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While RNA interference (RNAi) functions as an antiviral response in plants, nematodes, and arthropods, a
similar antiviral role in mammals has remained controversial. Three recent papers provide evidence that
either favors or challenges this hypothesis. Here, we discuss these new findings in the context of previous
research.RNA interference (RNAi) was first described in nematodes,
where injection of long double-stranded RNA (dsRNA) results
in the selective destruction of cognate mRNAs (Fire et al.,
1998). Subsequent work demonstrated that RNAi requires the
cleavage of these long dsRNAs into 22 bp dsRNAs bearing 2
nt 30 overhangs by the RNase III enzyme Dicer. One strand of
this small interfering RNA (siRNA) duplex is incorporated into
the RNA-induced silencing complex (RISC) and then guides
RISC to complementary mRNA species to initiate their cleavage
and hydrolysis or, in an alternative mode, their translational
repression (Bartel, 2009). The key component of RISC is
an Argonaute (Ago) protein, 27 of which are encoded in
C. elegans, although mammals only encode four Ago proteins.
While RNAi can downregulate the expression of cellular mRNA
species, it is likely that RNAi first evolved as an intrinsic immune
response to viral infection. In particular, all RNA viruses, except
retroviruses, must generate genomic complements through a
virus-encoded RNA-dependent RNA polymerase, followed by
transcription of the resultant complementary RNA. This yields
perfect dsRNAs that can function as templates for Dicer cleav-
age and siRNA generation. Furthermore, viruses also produce
structured RNAs and bidirectional RNAs, which can serve as
Dicer substrates. The resultant siRNAs can directly target viral
RNA species, and RNAi has thus been proposed as a key anti-
viral intrinsic immune response in plants, nematodes, and arthro-
pods (Figure 1). In support of RNAi being a relevant antiviral
mechanism, many viruses that infect these organisms have
evolved viral suppressors of RNAi (VSRs) that enhance virus
replication by attenuating RNAi (Wu et al., 2010). Among the
best-studied VSRs are the B2 proteins encoded by members
of the Nodaviridae (Aliyari et al., 2008), a family of RNA viruses
that primarily infects insects but includes members that can be
transmitted to vertebrates. B2 is a dsRNA binding protein that
can bind both dsRNA substrates, to prevent Dicer cleavage,
and siRNA duplex intermediates, to prevent RISC loading
(Chao et al., 2005).
While RNAi plays an important role in antiviral defense in plants
and many invertebrates, evidence in favor of an analogous func-
tion for RNAi in chordates has been lacking. Deep sequencing
of small RNA populations in various mammalian somatic cell
lines infected by a wide range of virus species has either entirely374 Cell Host & Microbe 14, October 16, 2013 ª2013 Elsevier Inc.failed to detect siRNAs derived from viral RNAs or has detected
these at only vanishingly low levels (e.g., Parameswaran et al.,
2010). This stands in contrast with the situation in nonchordates,
where siRNAs of viral origin are generally produced in readily
detectable amounts (Ding and Voinnet, 2007). Similarly, while
transfected long dsRNAs give rise to functional siRNAs in insect
cells, transfection of dsRNAs intomammalian somatic cells does
not produce functional siRNAs (Paddison et al., 2002). However,
dsRNAs introduced intomammalian somatic cells do function as
potent activators of the interferon response, a protein-based
antiviral system that is lacking in many organisms that use
RNAi as an antiviral pathway. Induction of the interferon system
results in a global shutdown of mRNA translation, degradation
of mRNAs, and eventually cell death (Figure 1). Interestingly,
this cellular response to dsRNA also results in the posttransla-
tional modification and inactivation of the key Ago component
of RISC in mammalian cells, as demonstrated by Seo et al.
(2013) in this issue of Cell Host & Microbe.
While mammalian cells are able to perform RNAi when trans-
fected with synthetic short RNA duplexes, this activity reflects
the fact that a second small RNA pathway is also present
(Figure 1). Colloquially referred to as siRNAs, these 22 bp
duplex RNAs are in fact analogs of the microRNA (miRNA)
duplex intermediates expressed by most eukaryotes. miRNAs
are initially transcribed as long, largely single-stranded primary
miRNA precursors that are processed by the RNA-specific
endoribonuclease Drosha in the nucleus, and Dicer, in the
cytoplasm, to release an 22 bp RNA duplex, bearing 2 nt 30
overhangs, that is essentially identical in structure to the siRNA
duplexes released by Dicer cleavage of long dsRNA in inverte-
brates. As in the case of the siRNA, one strand of the miRNA
duplex intermediate is loaded into RISC where it serves as a
guide RNA to target RISC to complementary mRNAs. Impor-
tantly, RISCs that encounter mRNAs that are fully com-
plementary to the miRNA can still be cleaved and degraded,
so that miRNAs and synthetic siRNAs are in fact functionally
indistinguishable in mammalian somatic cells (Zeng et al., 2003).
While mammalian somatic cells appear incapable of effec-
tively processing long dsRNAs into functional siRNAs, there
is evidence that this is not true for mammalian germ cells
and embryonic stem cells (ESCs), as well as some embryonic
Figure 1. Cartoon Depiction of Antiviral and
MicroRNA Pathways in Eukaryotes
Gray bars denote the type I interferon (IFN),
microRNA (miRNA), and RNA interference (RNAi)
systems. Black bars above the systems denote
their relative utilization as an antiviral mechanism
in different species. Plants, arthropods, nema-
todes, and mammalian embryonic stem cells
(ESCs) use both the miRNA and RNAi systems
but lack a functional IFN-I system. In contrast,
mammalian somatic cells have a functioning IFN-I
and miRNA system, but their utilization of RNAi
as an antiviral response is uncertain (depicted by
the gradient of the corresponding black bar). The
IFN-I system is initiated by detection of double-
stranded RNA (dsRNA) by pattern recognition
receptors (PRRs) resulting in the activation of
many transcription factors (TFs) that induce both
IFN-I and many antiviral genes that establish a
protein-mediated antiviral state. The miRNA sys-
tem processes dsRNA hairpins produced by the
host cell that are recognized and cleaved by
Dicer. One strand of the resulting duplex RNA
is subsequently loaded into the RNA-induced
silencing complex (RISC) where it downregulates
complementary target mRNAs (blue). The RNAi
system depicts viral dsRNA being cleaved by
Dicer to generate small interfering RNAs (siRNAs)
that are loaded into RISC to mediate an RNA-
dependent antiviral state by binding and cleaving
viral RNAs (red).
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dison et al., 2002). In each of these cell types, long dsRNAs can
induce the specific inhibition of cognate mRNA expression.
Moreover, deep sequencing of small RNAs expressed in ESCs
has identified a range of siRNAs that appear to derive from
dsRNAs of endogenous origin (Tam et al., 2008). These include
dsRNA derived from mobile genetic elements, such as retro-
transposons, whose repression in germ cells and ESCs is clearly
important to maintain genetic integrity. Of particular interest is a
report showing that DNA encoding a long dsRNA complemen-
tary to the mouse c-mos gene, when introduced into the mouse
genome, gave rise to readily detectable siRNA-mediated repres-
sion of c-Mos expression inmouse oocytes yet failed to generate
detectable siRNAs in somatic tissues from the same mouse (Ne-
jepinska et al., 2012). These data suggest that germ cells, ESCs,
and potentially other types of pluripotent stem cells process long
dsRNAs into functional siRNAs while somatic cells lack this abil-
ity. Of related interest, germ cells and ESCs also appear to be un-
able to mount a detectable interferon response (Burke et al.,
1978), thus suggesting that RNAi and the interferon response
play complementary roles in some contexts.
Antiviral RNAi Responses in Embryonic Stem Cells
The above data documenting the ability of ESCs to process long
dsRNAs into functional siRNAs suggested that ESCs might be
able to mount an RNAi response upon viral infection (Figure 1).
This hypothesis was recently tested by Maillard et al. (2013) by
infecting mouse ESCs with the picornavirus encephalomyocar-
ditis virus (EMCV). EMCV-derived siRNAs of the characteristic
22 nt size were observed both by deep sequencing and north-ern blot analysis and were derived in nearly equal amounts
from both the plus andminus strands of this (+)-sense RNA virus.
Virus-derived small RNAs displayed a phased 22 nt register
that is characteristic of the processive Dicer cleavage of long
dsRNAs. Finally, these 22 nt long EMCV-derived viral RNAs
were lost in Dicer-negative ESCs, confirming their origin as Dicer
cleavage products of viral RNAs.
Maillard et al. (2013) next infected ESCs with a nodavirus,
nodamura virus (NoV), which as noted above encodes a B2
protein, a potent VSR that functions by binding dsRNAs (Aliyari
et al., 2008). Very few virus-derived siRNAs were observed
upon infection of ESCs with WT NoV, but infection with a B2-
deficient NoV mutant (NoVDB2) produced increased levels of
siRNAs as monitored by deep sequencing, even though the
NoVDB2 mutant replicated at much lower levels. Importantly,
analysis of NoVDB2 replication in ESCs lacking all four mamma-
lian Ago proteins, and hence lacking functional RISCs, showed
that NoVDB2 could be partially rescued, consistent with the
hypothesis that the key function of B2 in NoV-infected ESCs
is repression of Dicer-mediated cleavage of viral dsRNAs to
generate functional antiviral siRNAs. It should be noted, howev-
er, that this same study also showed that loss of Dicer function,
and hence siRNA production, in EMCV-infected ESCs did not
enhance virus replication.
The idea that ESCs are distinct from somatic cells was
further supported by the finding that differentiation of ESCs
into embryoid bodies, with loss of pluripotency markers and
acquisition of tissue-specific markers, resulted in a substantial
decrease in the level of EMCV-derived siRNAs, although low
levels were still observed. Whether this low level of virus-derivedCell Host & Microbe 14, October 16, 2013 ª2013 Elsevier Inc. 375
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missing in somatic cells was not tested, and the molecular basis
for this apparent loss of RNAi competence is not currently
known. Together, these data provide evidence in favor of the
hypothesis that ESCs, and potentially other undifferentiated
cell types with stem cell and/or pluripotent characteristics, are
capable of generating siRNAs. However, it should be noted
that this study did not directly demonstrate antiviral RNAi. This
concept was suggested by the appearance of small RNAs and
the partial rescue of NoVDB2 in the absence of functional
RISC, but viral RNA cleavage or silencing was not assessed.
Antiviral RNAi Responses in Somatic Cells in Culture
While the evidence discussed above supporting the capacity of
ESCs to generate siRNAs after viral infection is compelling,
the issue of whether mammalian somatic cells can also do so
remains controversial. Despite a significant amount of data
suggesting the lack of an RNAi response to viral infection in
chordates, Li et al. (2013) argue that somatic cells do indeed
have this activity. In particular, although infection of baby ham-
ster kidney (BHK) cells by wild-type NoV did not produce detect-
able viral siRNAs, infection by the NoVDB2 VSR mutant did
result in small viral RNAs with the characteristic 22 nt size.
Many of these small RNAs were derived from the viral () strand,
which is present at low levels in cells infected by the (+)-stranded
NoV. However, these reads were present at extremely low
levels, just hundreds out of the millions of small RNA reads
analyzed. To address whether this low level of NoV-specific
siRNAs was nevertheless functionally relevant, Li et al. (2013)
demonstrated that replication of NoVDB2 in BHK cells was
rescued not only by expression of B2 but also by expression
of the Ebola virion protein 35 (VP35), which has been reported
to have VSR activity (Haasnoot et al., 2007). Of note, VP35 is
in fact a dsRNA binding protein that has been shown to also
block the interferon response (Prins et al., 2010). Whether NoV
B2 has the ability to block the interferon response is unclear.
However, dsRNAs are potent interferon inducers, and viral
dsRNA binding proteins such as Ebola virus VP35 and influenza
virus NS1 can antagonize this activity (Garcı´a-Sastre et al., 1998;
Prins et al., 2010). Li et al. (2013) found that a NoV mutant
bearing a single point mutation in B2, Arg to Glu at position
59, that blocks B2 VSR function was also highly attenuated.
However, as this same mutation also blocks dsRNA binding
(Aliyari et al., 2008), it does not distinguish between these
distinct but related activities.
As noted by Maillard et al. (2013), ‘‘demonstration of antiviral
activity of siRNAs entails the genetic rescue of VSR-deficient
viruses in RNAi-compromised host cells.’’ Maillard et al. (2013)
demonstrated this for NoV replication in ESCs (which lack any
interferon response) by showing that NoVDB2 could replicate
to higher levels in ESCs lacking all mammalian Ago proteins. A
similar experiment in somatic cells, for example, examining the
replication capacity of NoVDB2 in mouse embryo fibroblasts
lacking Dicer, would represent a critical first step to support
the claim that somatic cells have the capacity to elicit an antiviral
RNAi response. However, the demonstration that these viral
siRNAs are indeed able to effectively silence viral mRNAs
would be needed to directly prove that this pathway is indeed
important.376 Cell Host & Microbe 14, October 16, 2013 ª2013 Elsevier Inc.To explain earlier negative data, Li et al. (2013) propose that
the lack of detectable siRNAs of viral origin in somatic cells might
be because mammalian viruses encode VSRs of such potency
that siRNAs are not produced. They indeed observed that
wild-type NoV infection of BHK cells did not produce detectable
NoV siRNAs, while infection with NoVDB2 produced higher
levels, albeit at very low levels. Numerous groups have shown
in mammalian cells that replication of a wide range of viruses
can be effectively disrupted by expression of complementary
siRNAs (DeVincenzo, 2012), and viruses can be engineered to
express siRNAs that can inhibit endogenous mRNAs (tenOever,
2013). Thus, RNAi and silencing pathways are active at least
early after virus infection. Moreover, if all pathogenic viruses
indeed express powerful VSRs, then it is difficult to explain the
results of Maillard et al. showing that the picornavirus EMCV
produces readily detectable levels of siRNAs in infected ESCs
(Maillard et al., 2013), even though previous analysis of picorna-
virus-infected somatic cells in culture failed to detect analogous
siRNAs (Parameswaran et al., 2010). Instead, this discrepancy
suggests that there is an intrinsic difference in the ability of
ESCs to generate viral siRNAs, as compared to somatic cells,
that is not due to a viral activity. This idea is reinforced by data
from Maillard et al. (2013) showing that differentiation of ESCs
dramatically reduces their ability to produce EMCV-derived
siRNAs. Furthermore, although a small number of viral dsRNA
binding proteins, such as NoV B2 and Ebola virus VP35, can
indeed function as VSRs, efforts to demonstrate VSR function
of other viral proteins have been less successful, with recent
data arguing that some previously proposed VSRs, including
HIV-1 Tat and influenza virus NS1, do not block RNAi (Perez
et al., 2009; Sanghvi and Steel, 2011). Indeed, the demonstration
that even bacterial dsRNA binding proteins can function as
repressors of RNAi when introduced into plant cells (Lichner
et al., 2003) raises the question of the physiological relevance
of VSR activity detected by overexpression in heterologous
systems. In this context, it is particularly noteworthy that an
influenza virus lacking its putative ‘‘VSR’’ maintains its lethality
in interferon defective mice, suggesting that RNAi responses,
if present, are insufficient to suppress replication in the context
of a physiological infection (Garcı´a-Sastre et al., 1998). Lastly,
Seo et al. (2013) report in this issue that viral infection leads to
the inhibition of RISC function by inducing the posttranslational
modification of the Ago component of RISC. These authors
hypothesize that miRNA-programmed RISCs normally repress
the expression of host genes involved in antiviral innate immune
responses and that inhibition of RISC therefore enhances this
protective response. Should RNAi represent a bona fide antiviral
defense in somatic cells, it is difficult to explain how these
activities could coexist.
Thus, while the functional relevance of viral siRNAs in mam-
malian somatic cells remains an open question, it is also clear
that low levels of small RNAs that resemble siRNAs are produced
in some contexts. Mammalian Dicer is an exonuclease that can
cleave both dsRNAs and RNA stem loops, such as pre-miRNAs.
During RNA virus replication, there are undoubtedly RNAs of
both types produced that could be targeted by Dicer. A key
question, which remains to be addressed, is whether these
small RNAs direct silencing of viral RNAs and can truly attenuate
virus replication in somatic cells.
Cell Host & Microbe
MinireviewAntiviral RNAi Responses In Vivo
An important result presented by Li et al. (2013) is that infection of
suckling mice by NoVDB2 leads to viral siRNAs detectable not
only by deep sequencing but also by northern blot analysis.
This result shows that, in contrast to cultured somatic cells, a
significant number of cells in vivo that are susceptible to NoV
infection are also capable of generating these RNA species.
This may imply that there are significant numbers of cells with
stem-cell like characteristics in vivo that maintain the ability
to generate viral siRNAs. This may be particularly relevant in
newborn animals, such as suckling mice, which could retain
a higher number of cells with pluripotent potential than adult
animals. Alternatively, it is possible that there are populations
of somatic cells in vivo that retain the ability to generate
siRNAs from dsRNA substrates, thus suggesting that cells
cultured in vitro might not necessarily be representative of the
terminally differentiated, nondividing somatic cells that predom-
inate in vivo. Therefore, a detailed analysis of which cell types
produce these viral small RNAs is essential.
Li et al. (2013) demonstrate that NoVDB2 and an NoV bearing
the inactivating B2 point mutation described above are both
highly attenuated in vivo and differ from wild-type NoV in that
they produce readily detectable viral small RNAs. However,
whether the increased pathogenicity of the wild-type virus is
due to the lack of viral siRNAs remains an open question. To
address this question, mouse mutants lacking the ability to
mount antiviral interferon responses would need to be chal-
lenged with either viral mutant. The present data show that the
ability of these NoV mutants to express a functional viral dsRNA
binding protein is critical to their pathogenesis, rather than
definitively establishing that siRNAs are antiviral and these pro-
teins act through antagonism of such siRNAs. Nevertheless,
this result is certainly provocative and should prompt experi-
ments designed to examine the ability of pathogenic viruses,
either wild-type or mutant, to generate siRNAs in vivo and to
test whether these direct viral silencing and are thus functionally
relevant.
Conclusion
The recent publications by Maillard et al. (2013) and Li et al.
(2013) have resurrected a question that seemed to have been
resolved, i.e., does RNAi function as a protective antiviral
immune response in mammalian cells? The data from Maillard
et al. (2013) strongly suggest that ESCs are indeed able to
generate siRNAs that may function to reduce viral replication.
This fits nicely with the fact that the germline has additional
RNA-mediated silencing pathways that protect genome integrity
(Malone and Hannon, 2009). The data from Li et al. (2013) also
show that mice infected with mutant forms of NoV lacking a
functional B2 protein generate readily detectable levels of viral
small RNAs in vivo, and these same NoV mutants can also
generate siRNAs, albeit at low levels, in infected somatic cells
in culture. Unfortunately, the evidence for functional relevance
of these NoV-specific siRNAs in vivo or in vitro rests entirely on
the hypothesis that the NoV B2 protein acts as a highly selective
inhibitor of siRNA production and that the detected small
RNAs are capable of eliciting antiviral RNAi. As discussed above,
this is not entirely clear and would have been more convincing
if the replication of these B2-deficient NoV mutants had beenshown to be rescued in RNAi-deficient cells in culture but not
by mutations that inactivate dsRNA-induced interferon re-
sponses in mice. Lastly, recent data by Seo et al. (2013) suggest
that RISC is in fact nonfunctional as early as 8 hr after viral
infection in vivo, an observation that is difficult to reconcile
with the hypothesis that RNAi functions as an important antiviral
response.
While the preponderance of available evidence indicates
that RNAi is not a significant antiviral response in mammalian
somatic cells in culture, these recent data do suggest that
RNAi is active in ESCs and potentially other types of undifferen-
tiated cells. Moreover, the evidence for high levels of siRNAs
in suckling mice infected with a B2-deficient strain of NoV is
consistent with the idea that siRNAs may play a protective role
in vivo. Whether virus-directed RNA silencing is important
in the case of human viral pathogens is a critical question that
remains to be fully addressed.
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